Octagon Capital Advisors LP Sells 506,465 Shares of Pharvaris N.V. $PHVS

Octagon Capital Advisors LP cut its stake in shares of Pharvaris N.V. (NASDAQ:PHVS) by 75.4% in the 1st quarter, HoldingsChannel reports. The fund owned 165,000 shares of the company’s stock after selling 506,465 shares during the quarter. Pharvaris makes up 0.5% of Octagon Capital Advisors LP’s investment portfolio, making the stock its 26th largest position. Octagon Capital Advisors LP’s holdings in Pharvaris were worth $4,661,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in PHVS. Tudor Investment Corp ET AL bought a new position in shares of Pharvaris during the third quarter worth approximately $1,943,000. PSP Research LLC acquired a new stake in Pharvaris during the 4th quarter worth approximately $569,000. JPMorgan Chase & Co. boosted its stake in Pharvaris by 710.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock valued at $676,000 after purchasing an additional 23,743 shares during the period. Seven Fleet Capital Management LP bought a new stake in Pharvaris in the 4th quarter valued at $1,536,000. Finally, Eversept Partners LP bought a new stake in Pharvaris in the 4th quarter valued at $12,187,000.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Citigroup reiterated a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Citizens Jmp decreased their price target on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 13th. Royal Bank Of Canada decreased their price target on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research note on Monday, April 6th. Wedbush raised their price target on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Finally, Wolfe Research started coverage on shares of Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.08.

Pharvaris Price Performance

Shares of PHVS opened at $34.17 on Monday. The firm has a 50 day simple moving average of $32.45 and a two-hundred day simple moving average of $29.27. Pharvaris N.V. has a one year low of $19.12 and a one year high of $36.60. The company has a market cap of $2.24 billion, a P/E ratio of -10.75 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. On average, analysts expect that Pharvaris N.V. will post -2.97 earnings per share for the current fiscal year.

Insider Buying and Selling at Pharvaris

In related news, insider Anne Lesage sold 27,872 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.48, for a total transaction of $988,898.56. Following the completion of the sale, the insider directly owned 58,750 shares in the company, valued at $2,084,450. This represents a 32.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Anna Nijdam sold 2,670 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $30.87, for a total value of $82,422.90. Following the completion of the sale, the insider directly owned 46,275 shares in the company, valued at $1,428,509.25. This trade represents a 5.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 274,555 shares of company stock worth $8,880,601 over the last quarter.

Pharvaris Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.